NEW YORK – Amgen's Xgeva, which is used to treat bone disorders related to cancer, received an additional U.S. marketing approval. The Food and Drug Administration approved Xgeva as a treatment for ...
"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant. A follow-up analysis of ...
A breast cancer diagnosis is devastating. To hear that it has metastasized takes that devastation to another level. Amgen’s “Moments that Matter” campaign for bone metastases drug, Xgeva (denosumab), ...
Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...
Amgen wants to extend use of bone cancer drug Xgeva (denosumab) into the prevention setting, but analysts, not to mention the FDA’s own advisors, are not optimistic about its chances of securing the ...
Amgen today announced the FDA plans to decide by April 26 on its application to expand the use of its bone treatment drug Xgeva to prevent or delay the spread of advanced prostate cancer. The drug is ...
THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA™ (denosumab) significantly increased ...
The approval is based on data from the pivotal Phase 3 '482 study, the largest international multiple myeloma clinical trial ever conducted. Amgen announced that the Food and Drug Administration (FDA) ...
Amgen's bone-bulking drugs Xgeva and Prolia are winning market share from Novartis' (NVS) Zometa. Expanding across indications Xgeva and Prolia are different doses of the drug denosumab. They work by ...
XGEVA is the first fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL) – a protein essential for the formation, function and survival of osteoclasts, which break down ...
Biotech giant Amgen (NASDAQ:AMGN) said its bone drug, Xgeva, received a positive recommendation from the European Medicines Agency, putting it on the fast track for approval as a treatment for ...
THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results